Trial of Brentuximab Vedotin in CD30+ CTCL Meets Primary End Point

The phase 3 ALCANZA study evaluating brentuximab vedotin (Adcetris) met its primary endpoint, demonstrating a significant improvement in the rate of objective response lasting at least 4 months, for patients with CD30-expressing cutaneous T-cell lymphoma (CTCL).¹

Investigators enrolled 131 patients who received prior systemic or radiation therapy. Participants were randomly assigned to receive single-agent brentuximab vedotin or investigator’s choice of standard therapies, such as methotrexate and bexarotene.

The rate of objective response lasting at least 4 months was 56.3% in the brentuximab vedotin arm, compared with 12.5% in the comparator arm (P < .0001). The complete response rate, progression-free survival, and reduction in the burden of symptoms during treatment were better in the brentuximab vedotin arm.

Adverse events were consistent with previously reported data.

An abstract of the ALCANZA trial will be submitted for data presentation at the 58^th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA.                             

Reference

1. Takeda and Seattle Genetics announce positive data from phase 3 ALCANZA clinical trial of Adcetris (brentuximab vedotin) for CD30-expressing cutaneous T-cell lymphoma. Seattle Genetics website. http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2191428. Updated August 1, 2016. Accessed August 24, 2016.